Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) have earned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $68.60.

Several brokerages recently commented on ENTA. StockNews.com began coverage on shares of Enanta Pharmaceuticals in a research note on Thursday. They issued a “hold” rating for the company. Piper Sandler reissued an “overweight” rating and issued a $87.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, February 8th. JMP Securities reissued a “buy” rating and issued a $96.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 22nd. JPMorgan Chase & Co. dropped their price target on shares of Enanta Pharmaceuticals from $74.00 to $60.00 and set a “neutral” rating for the company in a research note on Wednesday, February 8th. Finally, SVB Leerink reaffirmed a “market perform” rating and set a $49.00 price target on shares of Enanta Pharmaceuticals in a research note on Thursday, February 9th.

Enanta Pharmaceuticals Stock Down 2.4 %

Shares of NASDAQ:ENTA opened at $43.42 on Friday. The company’s 50 day moving average price is $49.63 and its two-hundred day moving average price is $49.11. Enanta Pharmaceuticals has a 12-month low of $37.59 and a 12-month high of $79.50. The firm has a market cap of $907.04 million, a PE ratio of -7.46 and a beta of 0.40.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last issued its quarterly earnings results on Tuesday, February 7th. The biotechnology company reported ($1.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.52) by $0.13. Enanta Pharmaceuticals had a negative net margin of 146.93% and a negative return on equity of 36.59%. The company had revenue of $23.60 million during the quarter, compared to the consensus estimate of $22.48 million. During the same quarter in the prior year, the firm posted ($1.48) EPS. The firm’s quarterly revenue was down 14.5% on a year-over-year basis. On average, research analysts expect that Enanta Pharmaceuticals will post -7.36 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Paul J. Mellett sold 5,000 shares of Enanta Pharmaceuticals stock in a transaction dated Thursday, February 9th. The shares were sold at an average price of $53.76, for a total transaction of $268,800.00. Following the completion of the transaction, the chief financial officer now directly owns 83,463 shares in the company, valued at $4,486,970.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Jay R. Luly sold 27,912 shares of the firm’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $45.16, for a total transaction of $1,260,505.92. Following the transaction, the chief executive officer now directly owns 819,810 shares of the company’s stock, valued at $37,022,619.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Paul J. Mellett sold 5,000 shares of the firm’s stock in a transaction dated Thursday, February 9th. The shares were sold at an average price of $53.76, for a total transaction of $268,800.00. Following the transaction, the chief financial officer now directly owns 83,463 shares in the company, valued at $4,486,970.88. The disclosure for this sale can be found here. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ENTA. Russell Investments Group Ltd. raised its position in Enanta Pharmaceuticals by 2.9% in the third quarter. Russell Investments Group Ltd. now owns 21,324 shares of the biotechnology company’s stock worth $1,105,000 after acquiring an additional 603 shares during the period. Texas Permanent School Fund increased its stake in shares of Enanta Pharmaceuticals by 5.2% in the third quarter. Texas Permanent School Fund now owns 14,016 shares of the biotechnology company’s stock worth $727,000 after purchasing an additional 692 shares in the last quarter. Northern Trust Corp increased its stake in shares of Enanta Pharmaceuticals by 0.3% in the second quarter. Northern Trust Corp now owns 931,291 shares of the biotechnology company’s stock worth $44,022,000 after purchasing an additional 3,198 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Enanta Pharmaceuticals by 7.7% in the third quarter. Cubist Systematic Strategies LLC now owns 40,323 shares of the biotechnology company’s stock worth $2,092,000 after purchasing an additional 2,900 shares in the last quarter. Finally, Prudential Financial Inc. increased its stake in shares of Enanta Pharmaceuticals by 4.6% in the third quarter. Prudential Financial Inc. now owns 19,749 shares of the biotechnology company’s stock worth $1,024,000 after purchasing an additional 860 shares in the last quarter. 93.68% of the stock is owned by institutional investors.

About Enanta Pharmaceuticals

(Get Rating)

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.